← Back to Search

Selective Estrogen Receptor Modulator

Tamoxifen for High Blood Pressure (T3PAH Trial)

Phase 2

Waitlist Available

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 weeks

Awards & highlights

T3PAH Trial Summary

This trial will test whether tamoxifen is a safe and effective treatment for pulmonary arterial hypertension. TAPSE and other measures will be used to determine efficacy.

Eligible Conditions

High Blood Pressure
Lung Disease
Pulmonary Arterial Hypertension
Pulmonary Hypertension
Tamoxifen
Estrogen Receptor Antagonists
Hormone Antagonists
Estrogen

T3PAH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Transthoracic echocardiogram (ECHO)-based change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) measurement

Secondary outcome measures

Quality of life will be assessed using emPHasis-10 questionnaire. This will be administered at baseline and 12 and 24 weeks.

Quality of life will be assessed using the SF36 questionnaire. This will be administered at baseline and 12 and 24 weeks.

Six minute walk test distance (6MWTD)

Other outcome measures

HgbA1c

Plasma BNP

T3PAH Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: TamoxifenExperimental Treatment1 Intervention

20 mg po TID for 24 weeks

Group II: PlaceboPlacebo Group1 Intervention

Placebo arm

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Tamoxifen

2005

Completed Phase 4

~29860

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

856 Previous Clinical Trials

672,174 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacant spots in this medical trial for participants?

"Affirmative. Clinicaltrials.gov documents state that since it's launch on October 1st 2018, this trial has been actively recruiting patients from a single medical centre and is currently searching for 24 participants in total."

Answered by AI

For what maladies is Tamoxifen typically utilized?

"Commonly used to treat cancerous growths, tamoxifen can also be employed as a therapeutic intervention for ovarian cancer and ovulation induction therapy. Additionally, it is also prescribed in high-risk cases."

Answered by AI

Are there any other past studies which have involved Tamoxifen?

"Currently, 67 Tamoxifen-related research projects are in progress with 22 of those studies having achieved Phase 3 status. The majority of these clinical trials occur near Ann Arbor, Michigan; however, there are 7300 other locations conducting experiments on this drug."

Answered by AI

What potential harms are associated with taking Tamoxifen?

"There is limited evidence that Tamoxifen can be used safely, so it has been assigned a rating of 2."

Answered by AI

How many individuals are currently partaking in this clinical experiment?

"Affirmative. According to the clinical data found on clinicaltrials.gov, this research study is actively recruiting volunteers and was initially posted on October 1st 2018. 24 patients are needed across a single medical facility for this trial's completion."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

Eric Austin 2018. "Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03528902.